Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.02 +1.23%

+$0.04 today

Market cap
$220.03M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 5.46M

Average 3.33M

CABA Total Debt

Short-term and long-term borrowings combined.

Cabaletta Bio, Inc.NASDAQ: CABA

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 8.1% from a year ago

Total debt stood at $26.45M at the end of Q1 FY2026, down 8.1% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +74.1% a year.

Context

  • Total debt amounted to 17.9% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -8.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.45M-2.4% QoQ
Last fiscal yearDec 2025
$27.1M+73.7% YoY
Year agoMar 2025
$28.79M-8.1% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.1%——
1 year+73.7%——
3-year CAGR+74.1%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
27.1M USD
Year-over-year change
+73.7%

Total Debt vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -8.1% is the 6th highest of 11, against a peer median of -7.4%.
  • Total debt amounts to 17.9% of total assets for CABA, versus a peer median of 13.5%.
CABA Competitors
Total Debt for CABA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALLOAllogene Therapeutics, Inc.Mar 2026$81.05M USD-0.3%-6.3%20.5%
EDITEditas Medicine, Inc.Mar 2026$71.97M USD+131.2%+20.4%48.2%
HUMAHumacyte, Inc.Mar 2026$65.9M USD+315.8%+9.0%59.6%
LYELLyell Immunopharma, Inc.Mar 2026$48.85M USD-14.4%-9.0%13.9%
KYTXKyverna Therapeutics, Inc.Mar 2026$33.76M USD+386.5%+40.1%13.1%
CABACabaletta Bio, Inc.Mar 2026$26.45M USD-8.1%+74.1%17.9%
CAPRCapricor Therapeutics, Inc.Mar 2026$21.12M USD+356.7%+44.6%6.5%
PRQRProQR Therapeutics N.V.Mar 2026€13.7M EUR-16.0%-14.0%13.8%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$7.37M USD-21.6%-16.4%2.9%
IMMPImmutep LimitedDec 2025A$1.21M AUD-28.2%-2.1%0.8%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$634K USD-56.1%-35.4%0.2%
Peer median (excluding CABA) —-7.4%-4.2%13.5%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.22M81.61M193.24M163.96M82.98M
Short-term Investments024.94M48.01M050.62M
Net Receivables00000
Inventory00000
Other Current Assets1.97M2.29M02.71M5.27M
Total Current Assets124.54M108.83M244.49M166.68M138.87M
Property, Plant & Equipment (Net)1.44M7.57M7.45M16.08M21.05M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets357K565K1.71M6.23M5.16M
Total Non-current Assets1.8M8.13M9.16M22.31M26.21M
Total Assets126.34M116.97M253.65M185.05M165.08M
Account Payables2.33M2.46M4.55M4.92M6.64M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.07M1.33M40K8.36M9.8M
Total Current Liabilities8.38M9.49M15.99M27.09M50.15M
Long-term Debt00002.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities02.96M1.46M5.63M2.88M
Total Liabilities8.38M12.45M17.45M32.71M53.03M
Common Stock0001K1K
Retained Earnings(112.59M)(165.56M)(233.24M)(349.1M)(516.96M)
Accumulated OCI0(47K)39K025K
Other Stockholders Equity00000
Minority Interest00000
Total Equity117.96M104.52M236.2M152.34M112.05M
Total Debt05.14M5.02M15.6M27.1M
Net Debt(122.22M)(76.47M)(188.22M)(148.36M)(55.88M)

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.